قالب وردپرس درنا توس
Home / Health / Johnson and Johnson start testing COVID-19 vaccine after developing a primate immune response

Johnson and Johnson start testing COVID-19 vaccine after developing a primate immune response



Johnson & Johnson JNJ,
-0.19 percent.
She said on Thursday that her vaccine was protected against SARS-CoV-2, the virus that causes COVID-19, in preclinical studies. The vaccine provided a strong immune response as shown by “neutralizing antibodies” that successfully prevented subsequent infection and provided complete or near-complete lung protection against viruses in non-human primates, the company said. Based on the robustness of the data, the first phase 1

/ 2a clinical trial of the vaccine candidate Ad26.COV2.S in healthy volunteers was initiated in the United States and Belgium, the company reported. Discussions with partners are underway to begin the most important phase 3 clinical wait for a single vaccine dose compared to placebo in September, pending interim phase 1 and 2 data and approval by regulators, Johnson and Johnson said.


Source link